Horizon is a leading provider of research tools to support translational genomics research and the development of personalised medicines.
The company’s proprietary rAAV gene-editing technology, GENESIS, is industry-leading. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.Founded in 2007, Horizon has become one of the fastest growing biotechnology companies in Europe and now occupies a 20,000 sq. ft. of state-of-art research facility in Cambridge, UK. The company has grown its top-line revenue by greater than 100% every year since foundation, growth that is built upon a customer base that includes 100 academic, biotechnology, diagnostic and pharmaceutical companies.
